Rachel K. Harrison

Rachel K. Harrison

Auto-generated profile, based on publicly available information

Rachel K. Harrison

Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
RHRachel K. Harrison
Rachel K. Harrison
SLSamantha R. Lauhon
Samantha R. Lauhon
ZCZachary A. Colvin
Zachary A. Colvin
JMJennifer J. McIntosh
Jennifer J. McIntosh

11 December 2020 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
RHRachel K. Harrison
Rachel K. Harrison
MCMeredith Cruz
Meredith Cruz
AWAshley Wong
Ashley Wong
CDCaroline Davitt
Caroline Davitt
APAnna Palatnik
Anna Palatnik
Background: The decision to initiate pharmacotherapy is integral in the care for pregnant women with gestational diabetes mellitus (GDM). We sought to compare pregnancy outcomes between two threshold percentages of elevated glucose values prior to initiation of pharmacotherapy for GDM. We hypothesized that a lower threshold at pharmacotherapy initiation will be associated with lower rates of adverse perinatal outcomes. Methods: This was a retrospective cohort study of women with GDM delivering in a single tertiary care center. Pregnancy outcomes were compared using bivariable and multivariable analyses between women who started pharmacotherapy (insulin or oral hypoglycemic agent) after a failed trial of dietary modifications at two different ranges of elevated capillary blood glucose (CBG) values: Group 1 when 20–39% CBG values were above goal; Group 2 when ≥40% CBG values were above goal. The primary outcome was a composite GDM-associated neonatal adverse outcome that included: macrosomia, large for gestational age (LGA), shoulder dystocia, hypoglycemia, hyperbilirubinemia requiring phototherapy, respiratory distress syndrome, stillbirth, and neonatal demise. Secondary outcomes included cesarean delivery, preterm birth (< 37 weeks), neonatal intensive care unit (NICU) admission, and small for gestational age (SGA). Results: A total of 417 women were included in the study. In univariable analysis, the composite neonatal outcome was statistically significantly higher in Group 2 compared to Group 1 (47.9% vs. 31.4%, p = 0.001). In addition, rates of preterm birth (15.7% vs 7.4%, p = 0.011), NICU admission (11.7% vs 4.0%, p = 0.006), and LGA (21.2% vs 9.1% p = 0.001) were higher in Group 2. In contrast, higher rates of SGA were noted in Group 1 (8.0% vs. 2.9%, p = 0.019). There was no difference in cesarean section rates. These findings persisted in multivariable analysis after adjusting for confounding factors (composite neonatal outcome aOR = 0.50, 95%CI [0.31–0.78]). Conclusions: Initiation of pharmacotherapy for GDM when 20–39% of CBG values are above goal, compared to ≥40%, was associated with decreased rates of adverse neonatal outcomes attributable to GDM. This was accompanied by higher rates of SGA among women receiving pharmacotherapy at the lower threshold. Additional studies are required to identify the optimal threshold of abnormal CBG values to initiate pharmacotherapy for GDM.

13 January 2020 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
APAnna Palatnik
Anna Palatnik
RHRachel K. Harrison
Rachel K. Harrison
RWRebekah J. Walker
Rebekah J. Walker
MTMadhuli Y. Thakkar
Madhuli Y. Thakkar
LELeonard E. Egede
Leonard E. Egede
Objective: To compare the glycemic threshold for pharmacotherapy initiation in women with gestational diabetes (GDM) based on maternal race/ethnicity. Methods: A retrospective cohort study of women with GDM who received pharmacotherapy during pregnancy, in addition to diet and exercise, between 2015 and 2019 in a university center. The primary outcome was percent of elevated capillary blood glucoses (CBGs) prior to pharmacotherapy initiation. This was compared between four maternal racial and ethnic groups: non-Hispanic white (NHW), non-Hispanic black (NHB), Hispanic and other race and ethnicity group that included Asian, American Indian and Alaskan Native. Univariable and multivariable analyses were done to estimate whether there was an independent association between maternal race and ethnicity and the percent of elevated CBGs prior to pharmacotherapy initiation. Results: A total of 440 women met inclusion criteria. In univariable analysis, NHB women, Hispanic, and women of other race and ethnicity had higher percent of elevated CBGs prior to pharmacotherapy initiation, compared to NHW women (45.5 ± 22.5% for NHW, 65.2 ± 25.4% for NHB, 58.3 ± 21.7% for Hispanic and 51.6 ± 26.8% for other race and ethnicity, respectively, p < 0.001). After the adjustment for maternal demographic and clinical factors, maternal race and ethnicity remained to be significantly associated with timing of pharmacotherapy initiation, with women of racial and ethnic minority having a higher percent of elevated CBGs prior to pharmacotherapy initiation (18.1, 95% CI 11.3–25.0 for NHB, 13.2, 95% CI 5.0–21.4 for Hispanic, 9.8, 95% CI 2.6–16.9 for women of other race and ethnicity). Conclusion: A significant variation was identified in glycemic threshold for pharmacotherapy initiation in women with GDM across different maternal racial and ethnic groups with minority women starting pharmacotherapy at higher percent of elevated CBGs.

7 October 2019 in Case Reports in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
CJColin Johnson
Colin Johnson
CDCaroline Davitt
Caroline Davitt
RHRachel Harrison
Rachel Harrison
MCMeredith Cruz
Meredith Cruz
Twin pregnancies complicated by complete hydatidiform mole coexisting with a viable fetus are rare and may result in significant complications. We describe the expectant management and our surgical approach in a 27-year-old Rh-negative woman presenting with recurrent episodes of vaginal bleeding and a twin pregnancy consisting of a molar pregnancy coexisting with a normal fetus. Inpatient management was undertaken with close maternal and fetal monitoring until cesarean delivery of a healthy female infant and histopathologically confirmed complete hydatidiform molar pregnancy (karyotype 46XX) at 34 weeks with no evidence of malignancy.

12 August 2020 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
RHRachel K. Harrison
Rachel K. Harrison
APAnna Palatnik
Anna Palatnik

4 September 2019 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
ASAlyssa Stiff
Alyssa Stiff
RHRachel Harrison
Rachel Harrison
APAnna Palatnik
Anna Palatnik